GC
GILD icon

Gratry & Company’s Gilead Sciences GILD Stock Holding History

Gratry & Company’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,145
Closed -$346K – 82
2016
Q2 		$346K Sell
4,145
-870
-17% -$77.2K 0.27% 43
2016
Q1 		$461K Sell
5,015
-35
-0.7% -$3.16K 0.33% 44
2015
Q4 		$511K Sell
5,050
-155
-3% -$16.1K 0.33% 41
2015
Q3 		$511K Buy
5,205
+100
+2% +$11.1K 0.31% 42
2015
Q2 		$598K Hold
5,105
– – 0.31% 39
2015
Q1 		$501K Buy
+5,105
New +$518K 0.27% 51
2014
Q4 		– Sell
-4,685
Closed -$499K – 71
2014
Q3 		$499K Buy
+4,685
New +$459K 0.26% 48

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gratry & Company's GILD Position: Q3 2016 in Review

Gratry & Company sold out of Gilead Sciences (GILD) in Q3 2016, closing a stake of 4,145 shares — an estimated $346K sold.

Gratry & Company first reported a position in GILD in Q3 2014 and held it in 7 quarters. The position peaked at $598K in Q2 2015. 1,557 funds tracked by Wall St. Rank hold GILD as of Q3 2016.

  • Gratry & Company reported no remaining Gilead Sciences position as of Q3 2016 after selling out during the quarter.
  • Gratry & Company sold 4,145 Gilead Sciences shares in Q3 2016, an estimated $346K.
  • Gratry & Company first reported a position in Gilead Sciences in Q3 2014 and held it in 7 quarters.
  • Gratry & Company's Gilead Sciences position peaked at $598K in Q2 2015.
  • 1,557 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2016.

Based on Gratry & Company's 13F filing for Q3 2016, filed 4 Nov 2016.